Scolaris Content Display Scolaris Content Display

Comparison 1 Poor outcome, Outcome 1 Poor outcome, according to type of medication.
Figures and Tables -
Analysis 1.1

Comparison 1 Poor outcome, Outcome 1 Poor outcome, according to type of medication.

Comparison 1 Poor outcome, Outcome 2 Poor outcome, according to start of study medication.
Figures and Tables -
Analysis 1.2

Comparison 1 Poor outcome, Outcome 2 Poor outcome, according to start of study medication.

Comparison 2 Case fatality, Outcome 1 Case fatality, according to type of medication.
Figures and Tables -
Analysis 2.1

Comparison 2 Case fatality, Outcome 1 Case fatality, according to type of medication.

Comparison 2 Case fatality, Outcome 2 Case fatality, according to start of study medication.
Figures and Tables -
Analysis 2.2

Comparison 2 Case fatality, Outcome 2 Case fatality, according to start of study medication.

Comparison 3 Secondary ischaemia, Outcome 1 Clinical signs of secondary ischaemia.
Figures and Tables -
Analysis 3.1

Comparison 3 Secondary ischaemia, Outcome 1 Clinical signs of secondary ischaemia.

Comparison 3 Secondary ischaemia, Outcome 2 Infarction on CT.
Figures and Tables -
Analysis 3.2

Comparison 3 Secondary ischaemia, Outcome 2 Infarction on CT.

Comparison 4 Intracranial haemorrhagic complications, Outcome 1 Intracranial hemorrhagic complications according to type of medication.
Figures and Tables -
Analysis 4.1

Comparison 4 Intracranial haemorrhagic complications, Outcome 1 Intracranial hemorrhagic complications according to type of medication.

Comparison 4 Intracranial haemorrhagic complications, Outcome 2 Intracranial haemorrhagic complications according to start of study medication.
Figures and Tables -
Analysis 4.2

Comparison 4 Intracranial haemorrhagic complications, Outcome 2 Intracranial haemorrhagic complications according to start of study medication.

Comparison 5 Rebleeding, Outcome 1 Rebleeding according to type of medication.
Figures and Tables -
Analysis 5.1

Comparison 5 Rebleeding, Outcome 1 Rebleeding according to type of medication.

Comparison 1. Poor outcome

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Poor outcome, according to type of medication Show forest plot

7

997

Risk Ratio (M‐H, Fixed, 95% CI)

0.79 [0.62, 1.01]

1.1 Acetylsalicylic acid

3

264

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.51, 1.28]

1.2 Cataclot/OKY‐046

2

280

Risk Ratio (M‐H, Fixed, 95% CI)

0.88 [0.54, 1.44]

1.3 Dipyridamole

1

320

Risk Ratio (M‐H, Fixed, 95% CI)

0.86 [0.57, 1.29]

1.4 Ticlopidine

1

133

Risk Ratio (M‐H, Fixed, 95% CI)

0.37 [0.14, 0.98]

2 Poor outcome, according to start of study medication Show forest plot

7

997

Risk Ratio (M‐H, Fixed, 95% CI)

0.79 [0.62, 1.01]

2.1 Start study medication before aneurysm treatment

2

373

Risk Ratio (M‐H, Fixed, 95% CI)

0.88 [0.62, 1.25]

2.2 Start study medication after aneurysm treatment

5

624

Risk Ratio (M‐H, Fixed, 95% CI)

0.72 [0.51, 1.02]

Figures and Tables -
Comparison 1. Poor outcome
Comparison 2. Case fatality

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Case fatality, according to type of medication Show forest plot

7

1354

Risk Ratio (M‐H, Fixed, 95% CI)

1.01 [0.74, 1.37]

1.1 Acetylsalicylic acid

3

264

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.49, 1.93]

1.2 Cataclot/OKY‐046

2

280

Risk Ratio (M‐H, Fixed, 95% CI)

1.17 [0.57, 2.41]

1.3 Dipyridamole

1

677

Risk Ratio (M‐H, Fixed, 95% CI)

1.12 [0.74, 1.71]

1.4 Ticlopidine

1

133

Risk Ratio (M‐H, Fixed, 95% CI)

0.35 [0.10, 1.23]

2 Case fatality, according to start of study medication Show forest plot

7

1354

Risk Ratio (M‐H, Fixed, 95% CI)

1.01 [0.74, 1.37]

2.1 Start study medication before aneurysm treatment

2

730

Risk Ratio (M‐H, Fixed, 95% CI)

1.10 [0.74, 1.64]

2.2 Start study medication after aneurysm treatment

5

624

Risk Ratio (M‐H, Fixed, 95% CI)

0.88 [0.54, 1.45]

Figures and Tables -
Comparison 2. Case fatality
Comparison 3. Secondary ischaemia

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Clinical signs of secondary ischaemia Show forest plot

4

368

Risk Ratio (M‐H, Fixed, 95% CI)

0.79 [0.53, 1.16]

1.1 Acetylsalicylic acid

2

211

Risk Ratio (M‐H, Fixed, 95% CI)

1.34 [0.76, 2.34]

1.2 Cataclot/OKY‐046

1

24

Risk Ratio (M‐H, Fixed, 95% CI)

0.53 [0.24, 1.15]

1.3 Dipyridamole

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

1.4 Ticlopidine

1

133

Risk Ratio (M‐H, Fixed, 95% CI)

0.39 [0.17, 0.86]

2 Infarction on CT Show forest plot

3

395

Risk Ratio (M‐H, Fixed, 95% CI)

0.85 [0.66, 1.08]

2.1 Acetylsalicylic acid

2

211

Risk Ratio (M‐H, Fixed, 95% CI)

1.06 [0.76, 1.48]

2.2 Cataclot/OKY‐046

1

184

Risk Ratio (M‐H, Fixed, 95% CI)

0.64 [0.44, 0.92]

2.3 Dipyridamole

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

2.4 Ticlopidine

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

Figures and Tables -
Comparison 3. Secondary ischaemia
Comparison 4. Intracranial haemorrhagic complications

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Intracranial hemorrhagic complications according to type of medication Show forest plot

5

839

Risk Ratio (M‐H, Fixed, 95% CI)

1.36 [0.59, 3.12]

1.1 Acetylsalicylic acid

2

211

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.19, 4.76]

1.2 Cataclot/OKY‐046

2

280

Risk Ratio (M‐H, Fixed, 95% CI)

1.55 [0.48, 5.02]

1.3 Dipyridamole

1

348

Risk Ratio (M‐H, Fixed, 95% CI)

1.52 [0.26, 8.97]

1.4 Ticlopidine

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

2 Intracranial haemorrhagic complications according to start of study medication Show forest plot

5

839

Risk Ratio (M‐H, Fixed, 95% CI)

1.36 [0.59, 3.12]

2.1 Start study medication before aneurysm treatment

1

348

Risk Ratio (M‐H, Fixed, 95% CI)

1.52 [0.26, 8.97]

2.2 Start study medication after aneurysm treatment

4

491

Risk Ratio (M‐H, Fixed, 95% CI)

1.31 [0.51, 3.37]

Figures and Tables -
Comparison 4. Intracranial haemorrhagic complications
Comparison 5. Rebleeding

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Rebleeding according to type of medication Show forest plot

2

838

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.70, 1.38]

1.1 Acetylsalicylic acid

1

161

Risk Ratio (M‐H, Fixed, 95% CI)

1.70 [0.44, 6.57]

1.2 Cataclot/OKY‐046

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

1.3 Dipyridamole

1

677

Risk Ratio (M‐H, Fixed, 95% CI)

0.94 [0.67, 1.33]

1.4 Ticlopidine

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

Figures and Tables -
Comparison 5. Rebleeding